The following partnerships are focused on the discovery and development of novel Anticalin therapeutics.
 |
On April 12, 2011, Pieris announced the initiation of a therapeutic discovery and development partnership with Daiichi Sankyo in which the company will produce novel Anticalins against two Daiichi Sankyo targets. |
|
|
|
 |
Announced on January 10, 2011, Pieris is collaborating with Takeda San Francisco (TSF) to provide an Anticalin against a TSF target. |
|
|
|
|
|
In September 2010, the company signed a multi-year, multi-target collaboration with both Sanofi (formerly Sanofi-aventis) and Sanofi Pasteur across a broad spectrum of indications. |
|
|
|
 |
In September 2009, Pieris announced a deal focused on discovering novel treatments for serious ocular disorders with Allergan, Inc. |
